Xentuzumab (Anti-IGF-1)

Synonyms: BI 836845; Anti-Human IGF-1 and IGF-2 Recombinant Antibody

Catalog No.A2457 Purity:99%

Xentuzumab (Anti-IGF-1) is a recombinant a humanized monoclonal antibody that targets IGF ligands IGF-1 and IGF-2. Xentuzumab inhibits both of IGF-1 and IGF-2 growth-promoting signalling and suppresses AKT activation. MW: 145.5 KD.

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 7.53mg/ml Endotoxin Level: ＜1EU/mg

Choose Selective IGF-1R Inhibitors

Name	Citation	IGF-1R	Insulin Receptor	Others
Linsitinib (OSI-906)	190	+++	++	IRR
NVP-AEW541	64	++	++	FLT3,Tek,FLT1
GSK1904529A	26	+++	+++
NVP-ADW742	22	+
BMS-536924	24	++	+++	FAK,MEK,LCK
AG-1024	26	+	+
GSK1838705A	18	+++	++++	ALK
BMS-754807	50	++++	++++	TrkB,Met,TrkA
PQ 401	3	+
Picropodophyllin (PPP)	41	++++

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Xentuzumab (Anti-IGF-1) is a recombinant a humanized monoclonal antibody that targets IGF ligands IGF-1 and IGF-2. Xentuzumab inhibits both of IGF-1 and IGF-2 growth-promoting signalling and suppresses AKT activation. MW: 145.5 KD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1417158-65-6
Molecular Weight	145.5 kDa
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.